
|Videos|January 13, 2023
Exploring Treatment Options After First Line CDK4/6 Inhibitor plus Endocrine Therapy
Insights concerning treatment selection beyond the first line in patients with HR+ metastatic breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
3
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
4
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
5



















































